Advertisement covers CROI 2014

What Will HIV Treatment Look Like in 5 Years?

March 21, 2014


Calvin Cohen, M.D., M.S.

Cost vs. Benefit Decisions

"I think we are due for a collision between the economics of how do we save money versus what we've been doing, which is the best possible therapy for the patient.

"Our field continues to improve. There are exciting developments. There's improvements in things that are already pretty good, and making them even better. We still see new drugs. We still see coformulation. We also know that there are already, and still to come, generics of the existing drugs -- which have been really good, but not as good, based on the studies we see.

"So I think the really interesting question will be, do we, as clinicians, get to do what we're trained to do, which is to provide the best possible regimen, regardless of what it costs? Or are we forced to do just OK because a payer says, 'We're not paying for the best'?"

-- Calvin Cohen, M.D., M.S., Director of Research, Community Research Initiative of New England, Boston.

This article was provided by It is a part of the publication The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014).


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.